Analyst David Risinger from Leerink Partners maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at $210.00.
David Risinger has given his Buy rating due to a combination of factors including AbbVie’s strategic acquisitions and its financial outlook. Despite a slight reduction in the expected earnings per share (EPS) for 2025 due to the acquisition of Nimble Therapeutics and other assets, the company’s EPS remains within the updated guidance range. This indicates a strong potential for growth and stability.
Additionally, AbbVie’s long-term EPS growth is estimated at 9%, which is a positive indicator for future performance. The company’s net debt to total capital ratio is at a manageable 20%, suggesting a solid financial position. These elements combined support the Buy rating, reflecting confidence in AbbVie’s ability to deliver shareholder value over time.
In another report released on April 21, Scotiabank also initiated coverage with a Buy rating on the stock with a $210.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABBV in relation to earlier this year.